Validating endpoints for therapeutic trials in fecal incontinence

J. Noelting, A. R. Zinsmeister, Adil Eddie Bharucha

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: A 50% or greater reduction in the frequency of fecal incontinence (FI) recorded with daily bowel diaries is the primary endpoint in clinical trials of FI. Whether this difference is clinically important is unknown. The relationship between FI symptoms recorded with daily and weekly instruments is unknown. The contribution of psychological factors to quality of life (QOL) in FI is unclear. Methods: Fecal incontinence severity was assessed with daily bowel diaries and periodic questionnaires (fecal incontinence severity score [FISS], FIQOL, 36-Item Short Form Health Survey [SF-36], and hospital anxiety and depression scales) for 4 weeks before and during double-blind randomization to placebo or clonidine in 44 women with FI. The reduction in FI frequency was compared to the minimal clinically important difference (MCID) computed from the FISS. Endpoints of FI were compared between daily and weekly diaries. Key Results: The FISS exceeded the MCID in 75% and 83% of patients in whom the FI frequency declined by 50-74% and ≥75% respectively. Parameters of FI measured with daily and weekly instruments were significantly correlated. The daily parameters explained 71% of the inter-patient variation in the FISS. The SF-36 health scores, rather than the FISS rating, explained a majority of the inter-subject variation in FIQOL. Conclusions & Inferences: Most patients who report a ≥50% reduction in FI frequency experience a clinically important improvement. Weekly questionnaires accurately assess the severity of FI. Self-reported physical and mental health explained a greater proportion of the variance in FIQOL than FI symptom severity.

Original languageEnglish (US)
JournalNeurogastroenterology and Motility
DOIs
StateAccepted/In press - 2016

Fingerprint

Fecal Incontinence
Therapeutics

Keywords

  • Bowel diaries
  • Endpoints
  • Fecal incontinence
  • Quality of life

ASJC Scopus subject areas

  • Endocrine and Autonomic Systems
  • Gastroenterology
  • Physiology

Cite this

Validating endpoints for therapeutic trials in fecal incontinence. / Noelting, J.; Zinsmeister, A. R.; Bharucha, Adil Eddie.

In: Neurogastroenterology and Motility, 2016.

Research output: Contribution to journalArticle

@article{b72434b4a0e54c80a8b9cf549ab7bec3,
title = "Validating endpoints for therapeutic trials in fecal incontinence",
abstract = "Background: A 50{\%} or greater reduction in the frequency of fecal incontinence (FI) recorded with daily bowel diaries is the primary endpoint in clinical trials of FI. Whether this difference is clinically important is unknown. The relationship between FI symptoms recorded with daily and weekly instruments is unknown. The contribution of psychological factors to quality of life (QOL) in FI is unclear. Methods: Fecal incontinence severity was assessed with daily bowel diaries and periodic questionnaires (fecal incontinence severity score [FISS], FIQOL, 36-Item Short Form Health Survey [SF-36], and hospital anxiety and depression scales) for 4 weeks before and during double-blind randomization to placebo or clonidine in 44 women with FI. The reduction in FI frequency was compared to the minimal clinically important difference (MCID) computed from the FISS. Endpoints of FI were compared between daily and weekly diaries. Key Results: The FISS exceeded the MCID in 75{\%} and 83{\%} of patients in whom the FI frequency declined by 50-74{\%} and ≥75{\%} respectively. Parameters of FI measured with daily and weekly instruments were significantly correlated. The daily parameters explained 71{\%} of the inter-patient variation in the FISS. The SF-36 health scores, rather than the FISS rating, explained a majority of the inter-subject variation in FIQOL. Conclusions & Inferences: Most patients who report a ≥50{\%} reduction in FI frequency experience a clinically important improvement. Weekly questionnaires accurately assess the severity of FI. Self-reported physical and mental health explained a greater proportion of the variance in FIQOL than FI symptom severity.",
keywords = "Bowel diaries, Endpoints, Fecal incontinence, Quality of life",
author = "J. Noelting and Zinsmeister, {A. R.} and Bharucha, {Adil Eddie}",
year = "2016",
doi = "10.1111/nmo.12809",
language = "English (US)",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Validating endpoints for therapeutic trials in fecal incontinence

AU - Noelting, J.

AU - Zinsmeister, A. R.

AU - Bharucha, Adil Eddie

PY - 2016

Y1 - 2016

N2 - Background: A 50% or greater reduction in the frequency of fecal incontinence (FI) recorded with daily bowel diaries is the primary endpoint in clinical trials of FI. Whether this difference is clinically important is unknown. The relationship between FI symptoms recorded with daily and weekly instruments is unknown. The contribution of psychological factors to quality of life (QOL) in FI is unclear. Methods: Fecal incontinence severity was assessed with daily bowel diaries and periodic questionnaires (fecal incontinence severity score [FISS], FIQOL, 36-Item Short Form Health Survey [SF-36], and hospital anxiety and depression scales) for 4 weeks before and during double-blind randomization to placebo or clonidine in 44 women with FI. The reduction in FI frequency was compared to the minimal clinically important difference (MCID) computed from the FISS. Endpoints of FI were compared between daily and weekly diaries. Key Results: The FISS exceeded the MCID in 75% and 83% of patients in whom the FI frequency declined by 50-74% and ≥75% respectively. Parameters of FI measured with daily and weekly instruments were significantly correlated. The daily parameters explained 71% of the inter-patient variation in the FISS. The SF-36 health scores, rather than the FISS rating, explained a majority of the inter-subject variation in FIQOL. Conclusions & Inferences: Most patients who report a ≥50% reduction in FI frequency experience a clinically important improvement. Weekly questionnaires accurately assess the severity of FI. Self-reported physical and mental health explained a greater proportion of the variance in FIQOL than FI symptom severity.

AB - Background: A 50% or greater reduction in the frequency of fecal incontinence (FI) recorded with daily bowel diaries is the primary endpoint in clinical trials of FI. Whether this difference is clinically important is unknown. The relationship between FI symptoms recorded with daily and weekly instruments is unknown. The contribution of psychological factors to quality of life (QOL) in FI is unclear. Methods: Fecal incontinence severity was assessed with daily bowel diaries and periodic questionnaires (fecal incontinence severity score [FISS], FIQOL, 36-Item Short Form Health Survey [SF-36], and hospital anxiety and depression scales) for 4 weeks before and during double-blind randomization to placebo or clonidine in 44 women with FI. The reduction in FI frequency was compared to the minimal clinically important difference (MCID) computed from the FISS. Endpoints of FI were compared between daily and weekly diaries. Key Results: The FISS exceeded the MCID in 75% and 83% of patients in whom the FI frequency declined by 50-74% and ≥75% respectively. Parameters of FI measured with daily and weekly instruments were significantly correlated. The daily parameters explained 71% of the inter-patient variation in the FISS. The SF-36 health scores, rather than the FISS rating, explained a majority of the inter-subject variation in FIQOL. Conclusions & Inferences: Most patients who report a ≥50% reduction in FI frequency experience a clinically important improvement. Weekly questionnaires accurately assess the severity of FI. Self-reported physical and mental health explained a greater proportion of the variance in FIQOL than FI symptom severity.

KW - Bowel diaries

KW - Endpoints

KW - Fecal incontinence

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=84960194738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960194738&partnerID=8YFLogxK

U2 - 10.1111/nmo.12809

DO - 10.1111/nmo.12809

M3 - Article

C2 - 26948292

AN - SCOPUS:84978785970

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

ER -